Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
EyePoint Pharmaceuticals, Inc. (EYPT)
|
Add to portfolio |
|
|
|
| Price: |
$9.75
| | Metrics |
| OS: |
35.0
|
M
| |
|
|
| Market cap: |
$341
|
M
| |
|
|
|
Net cash:
|
$140
|
M
| |
$3.99
|
per share
|
|
EV:
|
$201
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
|
| |
|
|
|
EBIT
|
|
| |
|
|
| EPS |
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-05-22 | Dec-31-21 | Dec-05-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Jun-30-18 |
| Revenues | 41.4 | 41.4 | 36.9 | 36.9 | 34.4 | 20.4 | 4.6 | 3.0 |
| Revenue growth | 12.1% | 12.1% | 7.3% | | 69.1% | 345.5% | | -60.7% |
| Cost of goods sold | 0.0 | 0.0 | 0.0 | 0.0 | 2.5 | 2.5 | 0.0 | 0.0 |
| Gross profit | 41.4 | 41.4 | 36.9 | 36.9 | 32.0 | 17.9 | 4.6 | 3.0 |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 92.9% | 87.9% | 100.0% | 100.0% |
| Selling, general and administrative | | | | | | | | |
| Sales and marketing | 25.5 | 25.5 | 27.5 | 27.5 | 25.3 | 29.8 | 9.7 | 1.5 |
| Research and development | | | | | 17.4 | 15.4 | | 16.2 |
| General and administrative | | 34.8 | | 25.6 | 20.7 | 17.9 | 15.4 | 11.5 |
| EBITA | -100.7 | -97.6 | -59.1 | -52.8 | -34.8 | -45.4 | -39.0 | -25.3 |
| EBITA margin | -243.3% | -235.7% | -160.0% | -143.0% | -101.1% | -222.9% | -853.6% | -854.2% |
| Amortization of intangibles | 4.2 | 2.1 | 2.5 | 2.5 | 2.5 | 2.5 | | 1.0 |
| EBIT | -104.9 | -99.6 | -61.6 | -55.3 | -37.3 | -47.9 | -39.0 | -26.3 |
| EBIT margin | -253.3% | -240.6% | -166.6% | -149.6% | -108.3% | -235.0% | -853.6% | -887.3% |
| Pre-tax income | -102.3 | -102.3 | -58.4 | -58.4 | -45.4 | -56.8 | -86.1 | -53.2 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -102.3 | -102.3 | -58.4 | -58.4 | -45.4 | -56.8 | -86.1 | -53.2 |
| Net margin | -247.0% | -247.0% | -158.1% | -158.1% | -131.8% | -278.9% | -1884.2% | -1795.7% |
| |
| Diluted EPS | ($2.74) | ($2.74) | ($2.03) | ($2.03) | ($3.54) | ($5.44) | ($1.27) | ($1.15) |
| Shares outstanding (diluted) | 37.3 | 37.3 | 28.8 | 28.8 | 12.8 | 10.4 | 67.9 | 46.2 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|